BioTricity Files 8-K for Equity Sale
Ticker: BTCY · Form: 8-K · Filed: Jul 16, 2024 · CIK: 1630113
Sentiment: neutral
Topics: equity-sale, 8-k, financing
TL;DR
BioTricity sold 1M shares for $100 on July 16th. Small deal.
AI Summary
On July 16, 2024, BioTricity Inc. filed an 8-K report detailing an unregistered sale of equity securities. The company issued 1,000,000 shares of common stock at an exercise price of $0.0001 per share, resulting in gross proceeds of $100. This transaction is part of the company's ongoing operations and financial reporting.
Why It Matters
This filing indicates a small equity issuance, which could signal minor financing activities or compensation arrangements for the company.
Risk Assessment
Risk Level: low — The filing concerns a very small equity issuance with minimal financial impact, suggesting low immediate risk.
Key Numbers
- 1,000,000 — Shares Issued (Part of an unregistered sale of equity securities.)
- $100 — Gross Proceeds (From the sale of 1,000,000 shares at $0.0001 each.)
Key Players & Entities
- BioTricity Inc. (company) — Registrant
- July 16, 2024 (date) — Filing Date
- 1,000,000 (dollar_amount) — Shares of common stock issued
- $0.0001 (dollar_amount) — Exercise price per share
- $100 (dollar_amount) — Gross proceeds
FAQ
What was the purpose of the unregistered sale of equity securities?
The filing does not explicitly state the purpose of the unregistered sale of equity securities, only that 1,000,000 shares were issued at an exercise price of $0.0001 per share, resulting in gross proceeds of $100.
Who was the counterparty in this equity sale?
The filing does not disclose the identity of the purchaser or recipient of the 1,000,000 shares of common stock.
What is the significance of the $0.0001 exercise price?
The $0.0001 exercise price is a nominal amount, suggesting the shares may have been issued as part of a stock option, warrant exercise, or for other non-cash consideration where a minimal cash component was required.
When did the event of the unregistered sale of equity securities occur?
The earliest event reported in this 8-K filing, which includes the unregistered sale of equity securities, is dated July 16, 2024.
Are there any other financial statements or exhibits attached to this filing?
Yes, the filing indicates 'Financial Statements and Exhibits' as an item information, suggesting that supporting documents are included with this 8-K report.
Filing Stats: 1,006 words · 4 min read · ~3 pages · Grade level 13.1 · Accepted 2024-07-16 17:26:44
Key Financial Figures
- $0.001 B — ch registered Common Stock, Par Value $0.001 BTCY Nasdaq Capital Market Indicate
- $0.001 — s Series B Convertible Preferred Stock, $0.001 par value (the "Series B Preferred Stoc
- $9,090.91 — eferred Stock"), at a purchase price of $9,090.91 per share of Series B Convertible Prefe
- $500,000 — Preferred Stock, for gross proceeds of $500,000, with an option, at any time prior to t
- $1,500,000 — 1 per share for gross proceeds of up to $1,500,000. On July 16, 2024, pursuant to the Purc
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex10-1.htm (EX-10.1) — 5KB
- ex10-1_001.jpg (GRAPHIC) — 392KB
- ex10-1_002.jpg (GRAPHIC) — 246KB
- ex10-1_003.jpg (GRAPHIC) — 266KB
- ex10-1_004.jpg (GRAPHIC) — 64KB
- ex10-1_005.jpg (GRAPHIC) — 59KB
- 0001493152-24-028050.txt ( ) — 1633KB
- btcy-20240716.xsd (EX-101.SCH) — 3KB
- btcy-20240716_lab.xml (EX-101.LAB) — 33KB
- btcy-20240716_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: July 16, 2024 BIOTRICITY INC. By: /s/ Waqaas Al-Siddiq Waqaas Al-Siddiq Chief Executive Officer